Christopher Ellis

September 9, 2021

VHVI offers latest therapies to treat atrial fibrillation

Vanderbilt Heart and Vascular Institute continues to offer the latest in therapies to treat atrial fibrillation (AF or AFib), the most common cardiac arrhythmia.

By Matt Batcheldor
March 18, 2021

Device to treat AFib may eliminate need for blood thinners

Vanderbilt University Medical Center is participating in a trial for a device that could revolutionize the way patients are treated for atrial fibrillation (AF or AFib.)

By Matt Batcheldor
Christopher Ellis, MD, is studying a minimally invasive procedure to treat patients with longstanding atrial fibrillation.
October 22, 2020

Minimally invasive treatment option for AFib studied

A minimally invasive procedure that combines ligation of the left atrial appendage (LAA) with hybrid epicardial-endocardial ablation is a feasible, safe and effective method of treating patients with longstanding atrial fibrillation (AF or AFib), according to a new Vanderbilt-led study.

By Matt Batcheldor
September 17, 2020

New device may aid advanced heart failure patients

Vanderbilt Heart and Vascular Institute (VHVI) has implanted its first V-Wave, an interatrial shunt device, as a part of a multi-center clinical trial.

By Matt Batcheldor
Installing the wireless pacemaker requires only a minimally invasive surgery using a catheter inserted in a vein.
March 12, 2020

Tiny pacemaker helps keep patient’s heart in rhythm

In February, Martha Hawks became the Southeast’s first recipient of the Medtronic Micra AV, the latest version of the tiny pacemaker that Vanderbilt Heart and Vascular Institute began testing in a clinical trial in 2014. The FDA approved the latest device in January.

By Matt Batcheldor
February 7, 2019

Device helps heart patients ditch blood thinners

For the first time in 27 years, Jerry Flowers is looking at life without using blood thinners, thanks to a small device that was implanted in his heart in a clinical trial at Vanderbilt Heart and Vascular Institute (VHVI).

By Matt Batcheldor
February 9, 2017

VUMC testing device to reduce stroke risk in arrhythmia patients

Vanderbilt University Medical Center (VUMC) is the first in the state to enroll patients in a clinical trial testing the effectiveness of the newest implantable device used to reduce stroke risk in patients with non-valvular atrial fibrillation (AF), the most common form of arrhythmia.
By Jessica Pasley
August 25, 2016

Device helps curb atrial fibrillation patients’ stroke risk

Peggy Tubb doesn’t recall her exact reaction when she was told she could stop taking blood thinners to treat atrial fibrillation (AF), but the news changed her life.
By Jessica Pasley
June 17, 2015

Vanderbilt Heart offers alternative to blood thinners for atrial fibrillation

Vanderbilt Heart and Vascular Institute now offers patients with atrial fibrillation (AF) an alternative treatment to reduce their risk of stroke, potentially avoiding the long-term use of blood thinners such as warfarin.
By Kathy Whitney
September 18, 2014

Heart Institute testing world’s tiniest pacemaker

Vanderbilt Heart and Vascular Institute is participating in a global clinical trial to test the safety and efficacy of the world’s smallest pacemaker.
By Kathy Whitney
August 8, 2013

‘Envelope’ reduces cardiac implant infections

Vanderbilt Heart and Vascular Institute is the first in the United States to use a new fully resorbable “envelope” that encloses implantable cardiac devices, such as pacemakers and internal cardioverter defibrillators (ICDs), and helps prevent surgical site infections.
By Kathy Whitney
August 1, 2013

New technique eases stroke risk for atrial fibrillation patients

People with the most common irregular heart rhythm known as atrial fibrillation (AF) are at greater risk for stroke due to the formation of clots in the left atrial appendage (LAA), a small pouch which empties blood into the left atrium.
By Kathy Whitney
April 11, 2013

Patient undergoes surgical first to treat his arrhythmia

The state of Michael Stanbery’s health was shocking.
By Kathy Whitney
1 2